Prosecution Insights
Last updated: April 19, 2026

Examiner: STOCKTON, LAURA LYNNE

Tech Center 1600 • Art Units: 1626

This examiner grants 75% of resolved cases

Performance Statistics

75.2%
Allow Rate
+15.2% vs TC avg
1368
Total Applications
+33.7%
Interview Lift
920
Avg Prosecution Days
Based on 1342 resolved cases, 2023–2026

Rejection Statute Breakdown

1.2%
§101 Eligibility
22.1%
§102 Novelty
21.1%
§103 Obviousness
34.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18010642 COMPOUNDS AND METHODS FOR BLOCKING APOPTOSIS AND INDUCING AUTOPHAGY Final Rejection President and Fellows of Harvard College
17642662 CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF Non-Final OA President and Fellows of Harvard College
17742378 COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME Final Rejection FUJIFILM Corporation
13895089 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Final Rejection SUMITOMO PHARMA CO., LTD.
17927762 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS Final Rejection CHIESI FARMACEUTICI S.P.A.
18261629 KRAS G12C INHIBITORS Non-Final OA BeiGene Switzerland GmbH
17369032 UBE2K MODULATORS AND METHODS FOR THEIR USE Final Rejection BPGbio, Inc.
17964423 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF Non-Final OA BioSplice Therapeutics, Inc.
17972008 PROCESS FOR THE PREPARATION OF SODIUM 4-(2-((1E,3E,5E,7Z)-7-(1,1-DIMETHYL-3-(4-SULFONATOBUTYL)-1H-BENZO[e]INDOL-2(3H)-YLIDENE) HEPTA-1,3,5-TRIENYL)-1,1-DIMETHYL-1H-BENZO[e]INDOLIUM-3-YL) BUTANE-1-SULFONATE (INDOCYANINE GREEN) Final Rejection BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.
18258675 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Non-Final OA ACTELION PHARMACEUTICALS LTD
18274867 NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF Non-Final OA TXINNO BIOSCIENCE INC.
18260004 TRICYCLIC COMPOUND AND USE THEREOF Non-Final OA NANJING ZAIMING PHARMACEUTICAL CO., LTD.
17764329 INHIBITOR OF BTK AND MUTANTS THEREOF Final Rejection Newave Pharmaceutical Inc.
18129310 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE Non-Final OA LT MATERIALS CO., LTD.
17998234 COMPOUNDS AS BCL-2 INHIBITORS Non-Final OA Fochon Biosciences, Ltd.
17768725 ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY Final Rejection Delix Therapeutics, Inc.
17926900 COMPOUND AND APPLICATION THEREOF Non-Final OA GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD
17802886 INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS Non-Final OA Immunologik GmbH
17915474 FLUORESCENT LABELING AGENT AND FLUORESCENT DYE Non-Final OA artience Co., Ltd.
17759807 PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND Final Rejection FRONTIER BIOTECHNOLOGIES INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month